These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25420674)

  • 1. Pharmacogenomic medicine in autism: challenges and opportunities.
    Bowers K; Lin PI; Erickson C
    Paediatr Drugs; 2015 Apr; 17(2):115-24. PubMed ID: 25420674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential benefits and limits of psychopharmacological therapies in pervasive developmental disorders.
    Molteni M; Nobile M; Cattaneo D; Radice S; Clementi E
    Curr Clin Pharmacol; 2014; 9(4):365-76. PubMed ID: 24050744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of risperidone in children with autism spectrum disorder.
    Chavez B; Chavez-Brown M; Rey JA
    Ann Pharmacother; 2006 May; 40(5):909-16. PubMed ID: 16684811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on pharmacotherapy for autism spectrum disorder in children and adolescents.
    Ji N; Findling RL
    Curr Opin Psychiatry; 2015 Mar; 28(2):91-101. PubMed ID: 25602248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders.
    Spooren W; Lindemann L; Ghosh A; Santarelli L
    Trends Pharmacol Sci; 2012 Dec; 33(12):669-84. PubMed ID: 23084458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel treatments in autism spectrum disorders: from synaptic dysfunction to experimental therapeutics.
    Canitano R
    Behav Brain Res; 2013 Aug; 251():125-32. PubMed ID: 23202136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?
    Guest PC; Martins-de-Souza D
    Adv Exp Med Biol; 2017; 974():49-67. PubMed ID: 28353224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subphenotype-dependent disease markers for diagnosis and personalized treatment of autism spectrum disorders.
    Hu VW
    Dis Markers; 2012; 33(5):277-88. PubMed ID: 22960334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of executive functions in social impairment in Autism Spectrum Disorder.
    Leung RC; Vogan VM; Powell TL; Anagnostou E; Taylor MJ
    Child Neuropsychol; 2016; 22(3):336-44. PubMed ID: 25731979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments.
    Huffman LC; Sutcliffe TL; Tanner IS; Feldman HM
    J Dev Behav Pediatr; 2011 Jan; 32(1):56-68. PubMed ID: 21160435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy to control behavioral symptoms in children with autism.
    Doyle CA; McDougle CJ
    Expert Opin Pharmacother; 2012 Aug; 13(11):1615-29. PubMed ID: 22550944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making progress in autism drug discovery.
    Chadman KK
    Expert Opin Drug Discov; 2014 Dec; 9(12):1389-91. PubMed ID: 25251213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of autism spectrum disorder.
    Brown JT; Eum S; Cook EH; Bishop JR
    Pharmacogenomics; 2017 Mar; 18(4):403-414. PubMed ID: 28244813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing drugs for core social and communication impairment in autism.
    Posey DJ; Erickson CA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):787-801, viii-ix. PubMed ID: 18775370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discovery for autism spectrum disorder: challenges and opportunities.
    Ghosh A; Michalon A; Lindemann L; Fontoura P; Santarelli L
    Nat Rev Drug Discov; 2013 Oct; 12(10):777-90. PubMed ID: 24080699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders.
    Findling RL
    J Clin Psychiatry; 2005; 66 Suppl 10():26-31. PubMed ID: 16401147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder.
    Dinnissen M; Dietrich A; van den Hoofdakker BJ; Hoekstra PJ
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):111-24. PubMed ID: 25385293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychopharmacological interventions in autism spectrum disorder.
    Politte LC; Henry CA; McDougle CJ
    Harv Rev Psychiatry; 2014; 22(2):76-92. PubMed ID: 24614763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment options for autism spectrum disorders in children and adolescents.
    Leskovec TJ; Rowles BM; Findling RL
    Harv Rev Psychiatry; 2008; 16(2):97-112. PubMed ID: 18415882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autism and associated behavioral disorders: pharmacotherapeutic intervention.
    Gilman JT; Tuchman RF
    Ann Pharmacother; 1995 Jan; 29(1):47-56. PubMed ID: 7711345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.